CN1301173A - 用于预防和治疗脑组织损伤的含有半胱氨酸蛋白酶抑制剂的药用组合物 - Google Patents

用于预防和治疗脑组织损伤的含有半胱氨酸蛋白酶抑制剂的药用组合物 Download PDF

Info

Publication number
CN1301173A
CN1301173A CN99806167A CN99806167A CN1301173A CN 1301173 A CN1301173 A CN 1301173A CN 99806167 A CN99806167 A CN 99806167A CN 99806167 A CN99806167 A CN 99806167A CN 1301173 A CN1301173 A CN 1301173A
Authority
CN
China
Prior art keywords
formula
carbon atoms
pharmaceutical composition
brain tissue
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99806167A
Other languages
English (en)
Chinese (zh)
Inventor
东光佳
吉田征夫
坂本雄二
井上淳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Publication of CN1301173A publication Critical patent/CN1301173A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN99806167A 1998-03-20 1999-03-17 用于预防和治疗脑组织损伤的含有半胱氨酸蛋白酶抑制剂的药用组合物 Pending CN1301173A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP7228098 1998-03-20
JP72280/1998 1998-03-20

Publications (1)

Publication Number Publication Date
CN1301173A true CN1301173A (zh) 2001-06-27

Family

ID=13484725

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99806167A Pending CN1301173A (zh) 1998-03-20 1999-03-17 用于预防和治疗脑组织损伤的含有半胱氨酸蛋白酶抑制剂的药用组合物

Country Status (19)

Country Link
US (1) US6342531B1 (enExample)
EP (1) EP1064021B1 (enExample)
JP (1) JP2002507579A (enExample)
KR (1) KR20010041967A (enExample)
CN (1) CN1301173A (enExample)
AR (1) AR018784A1 (enExample)
AT (1) ATE275420T1 (enExample)
AU (1) AU2852699A (enExample)
BR (1) BR9908948A (enExample)
CA (1) CA2324566A1 (enExample)
DE (1) DE69919995T2 (enExample)
ES (1) ES2224613T3 (enExample)
HU (1) HUP0101428A2 (enExample)
ID (1) ID27507A (enExample)
MX (1) MXPA00009188A (enExample)
MY (1) MY133063A (enExample)
NO (1) NO20004679L (enExample)
PL (1) PL342970A1 (enExample)
WO (1) WO1999048522A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7766300A (en) * 1999-10-07 2001-05-10 Novaneuron Inc. Gene necessary for striatal function, uses thereof, and compounds for modulatingsame
JPWO2002034252A1 (ja) 2000-10-26 2004-03-04 千寿製薬株式会社 ジペプチジルアルデヒド誘導体含有医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011850A2 (en) 1990-12-28 1992-07-23 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
ATE239698T1 (de) 1995-10-25 2003-05-15 Senju Pharma Co Angiogenese hemmer

Also Published As

Publication number Publication date
PL342970A1 (en) 2001-07-16
MXPA00009188A (es) 2002-04-24
EP1064021B1 (en) 2004-09-08
ES2224613T3 (es) 2005-03-01
ID27507A (id) 2001-04-12
KR20010041967A (ko) 2001-05-25
NO20004679D0 (no) 2000-09-19
ATE275420T1 (de) 2004-09-15
DE69919995D1 (de) 2004-10-14
DE69919995T2 (de) 2005-09-22
US6342531B1 (en) 2002-01-29
AR018784A1 (es) 2001-12-12
BR9908948A (pt) 2000-11-21
MY133063A (en) 2007-10-31
WO1999048522A1 (en) 1999-09-30
JP2002507579A (ja) 2002-03-12
NO20004679L (no) 2000-10-26
CA2324566A1 (en) 1999-09-30
EP1064021A1 (en) 2001-01-03
AU2852699A (en) 1999-10-18
HUP0101428A2 (hu) 2001-09-28

Similar Documents

Publication Publication Date Title
KR100849999B1 (ko) 두통, 편두통, 구역질 및 구토를 위한 약학적 조성물
US20080113973A1 (en) Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-2
JP2012025756A (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
US8222241B2 (en) Use of dimiracetam in the treatment of chronic pain
JP2002537258A5 (enExample)
JP2008539250A (ja) アテローム性動脈硬化症を処置するための方法
AU2018298012A1 (en) Statin compositions and methods for use in treating synucleinopathies
WO1998006391A1 (en) Pharmaceutical compositions comprising tyrphostins
US20090312311A1 (en) Combination of organic compounds
JP2003503457A (ja) 心臓血管合併症の治療用薬剤の製造におけるアンギオテンシンｉｉ１型受容体アンタゴニストの使用
EP1064021B1 (en) Use of cysteinprotease inhibitors for the manufacture of a medicament for prevention and treatment of brain tissue impairment due to hypertensive encephalopathy or encephalothlipsis.
CA2544136C (fr) Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires
US6455553B1 (en) Method for treating a demyelinating condition
KR100379155B1 (ko) 새로운 진통제 조성물
US20050059741A1 (en) Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-1
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
HK1209053B (en) Use of dimiracetam in the treatment of chronic pain
HK1187244A (en) Use of dimiracetam in the treatment of chronic pain
WO2003099332A1 (en) Medicinal composition for inhibiting the expression of atp-citrate lyase and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication